{"disease":{"id":"breast-cancer-metastases","name":"breast cancer metastases"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04075305","title":"The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","phase":"","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT06544668","title":"A Study for Dynamic Prediction Model of Breast Cancer Bone Metastases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03924609","title":"Impact of Intensive Follow-up for Bone Metastasis on Characteristics and Prognosis of Chinese Breast Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1500,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06555354","title":"MicroRNAs and Prognosis in Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1432,"lead_sponsor_name":"Casa Sollievo della Sofferenza IRCCS","has_results":false},{"nct_id":"NCT02051218","title":"Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1380,"lead_sponsor_name":"Swiss Cancer Institute","has_results":false},{"nct_id":"NCT00097487","title":"A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT06093022","title":"Surgical or Medical Treatment of Breast Cancer Metastasis: A Multicentre Observational Study","phase":"","overall_status":"RECRUITING","enrollment_count":720,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04486495","title":"Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":549,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT06392217","title":"clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT02410044","title":"Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT03500380","title":"A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":301,"lead_sponsor_name":"RemeGen Co., Ltd.","has_results":false},{"nct_id":"NCT04817813","title":"Long-term Outcomes After Breast Cancer Liver Metastasis Surgery: an European, Retrospective, Snapshot Study","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Hospital Miguel Servet","has_results":false},{"nct_id":"NCT06321640","title":"Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.","phase":"","overall_status":"UNKNOWN","enrollment_count":265,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT07100600","title":"Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT04079049","title":"BreCLIM-2 - A RCT Investigating Local Treatment for Breast Cancer Liver Metastases","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Umeå University","has_results":false},{"nct_id":"NCT03143322","title":"Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":168,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT02308020","title":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":162,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT04137406","title":"Role of SIRT1 in Regulation of Epithelial-to-mesenchymal Transition in Breast Cancer Lymph Nodes Metastasis","phase":"","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT04158947","title":"A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":130,"lead_sponsor_name":"xuexin he","has_results":false},{"nct_id":"NCT04744506","title":"Targeted Resection of Axillary Metastatic Lymph Nodes After Breast Cancer Neoadjuvant Chemotherapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":126,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04760431","title":"TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06764940","title":"A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Biostar Pharma, Inc.","has_results":false},{"nct_id":"NCT07251868","title":"Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT05144867","title":"Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Breast Cancer With Brain Oligometastasis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":98,"lead_sponsor_name":"Post Graduate Institute of Medical Education and Research, Chandigarh","has_results":false},{"nct_id":"NCT06718933","title":"Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04348916","title":"Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":66,"lead_sponsor_name":"Oncorus, Inc.","has_results":false},{"nct_id":"NCT00807859","title":"Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT05872347","title":"Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Shanghai Pharmaceuticals Holding Co., Ltd","has_results":false},{"nct_id":"NCT07177950","title":"A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":51,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT02286843","title":"Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?","phase":"NA","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT06339658","title":"ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"Hospital Universitari de Bellvitge","has_results":false},{"nct_id":"NCT04420598","title":"DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"MedSIR","has_results":true},{"nct_id":"NCT03449238","title":"Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT06937281","title":"SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT07018505","title":"EpCAM-Targeted Surface-Enhanced Raman Spectroscopy Nanotags for Rapid Evaluation of Surgical Margins and Sentinel Lymph Node Metastasis Status in Breast Cancers","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Yunnan Cancer Hospital","has_results":false},{"nct_id":"NCT06713161","title":"Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Yunnan Cancer Hospital","has_results":false},{"nct_id":"NCT04582968","title":"Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":39,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06793332","title":"BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":39,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04334330","title":"Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":34,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT00566618","title":"Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT04167605","title":"Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","has_results":false},{"nct_id":"NCT03933982","title":"A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06152822","title":"Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT06418594","title":"Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Beijing 302 Hospital","has_results":false},{"nct_id":"NCT06165419","title":"Definitive Radiation for High-Risk Spine Metastases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":26,"lead_sponsor_name":"Stony Brook University","has_results":false},{"nct_id":"NCT01724606","title":"Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03304210","title":"PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University Hospital, Ghent","has_results":true},{"nct_id":"NCT01862900","title":"Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Providence Health & Services","has_results":false},{"nct_id":"NCT03807765","title":"Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":false},{"nct_id":"NCT02650752","title":"Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}